+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying MZE782 in adults with Phenylketonuria PKU to evaluate its safety, tolerability, and effectiveness. This Phase 2 trial is designed as a randomized, double-blind, placebo-controlled, dose-ranging study to assess how well MZE782 works and how safe it is for people aged 18 to 75 with PKU. Maze Therapeutics is leading this research to better understand treatment options for this condition. Participants will be assigned to groups receiving either low or high doses of MZE782 tablets or a placebo. Some groups may need to stop certain PKU medications before starting the study treatment. The study measures include changes in blood phenylalanine levels and drug concentrations over several weeks. The treatment period extends from baseline through Week 17, with specific assessments at Weeks 1, 2, 3, 4, 8, 10, 13, and 17. During the study, participants will undergo regular blood tests to monitor phenylalanine levels and drug concentrations. Safety will be closely observed by tracking any adverse events from Week 0 to Week 17. Participants must keep their diet and protein intake consistent and may have to stop some PKU medications according to group assignments. The total study duration for participants is up to about 17 weeks, including follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 2
9 locations
I

Actively Recruiting

Researchers are studying the natural progression and variations of muscle disease caused by genetic changes in the TNNT1 gene, specifically focusing on autosomal recessive TNNT1-associated myopathy, including infantile-onset and childhood-onset forms of nemaline rod myopathy. The study aims to define important outcome measures to support future clinical trials of new treatments. This observational study welcomes children and adults worldwide and includes both prospective and cross-sectional groups. Participants in the prospective group join soon after diagnosis during early infancy and are followed over time with repeated assessments until they reach key study outcomes. Those in the cross-sectional group provide their information once at any time after diagnosis. Assessments include vital signs, physical exams, growth and motor milestone documentation, blood tests, heart ultrasounds echocardiograms, and chest X-rays. These evaluations happen at participants homes, the Clinic for Special Children, or partnering clinical sites, depending on individual circumstances. During the study, participants undergo regular monitoring of their health and development. The research team collects detailed medical history, physical findings, and growth measurements. The main outcome measured is event-free survival over up to 15 years, with secondary outcomes including motor milestones and overall thriving. The studys duration spans several years, allowing long-term observation of disease progression under current treatments.

All AgesAll Genders
1 location